Discovery of imidazo[1,2-a]-pyridine inhibitors of pan-PI3 kinases that are efficacious in a mouse xenograft model

Bioorganic & Medicinal Chemistry Letters
Wooseok HanSabina Pecchi

Abstract

Alterations in PI3K/AKT signaling are known to be implicated with tumorigenesis. The PI3 kinases family of lipid kinases has been an attractive therapeutic target for cancer treatment. Imidazopyridine compound 1, a potent, selective, and orally available pan-PI3K inhibitor, identified by scaffold morphing of a benzothiazole hit, was further optimized in order to achieve efficacy in a PTEN-deleted A2780 ovarian cancer mouse xenograft model. With a hypothesis that a planar conformation between the core and the 6-heteroaryl ring will allow for the accommodation of larger 5'-substituents in a hydrophobic area under P-loop, SAR efforts focused on 5'-alkoxy heteroaryl rings at the 6-position of imidazopyridine and imidazopyridazine cores that have the same dihedral angle of zero degrees. 6'-Alkoxy 5'-aminopyrazines in the imidazopyridine series were identified as the most potent compounds in the A2780 cell line. Compound 14 with 1,1,1-trifluoroisopropoxy group at 6'-position demonstrated excellent potency and selectivity, good oral exposure in rats and in vivo efficacy in A2780 tumor-bearing mouse. Also, we disclose the X-ray co-crystal structure of one enantiomer of compound 14 in PI3Kα, confirming that the trifluoromethyl group fit...Continue Reading

References

May 31, 2002·Acta Crystallographica. Section D, Biological Crystallography·Robin Taylor
Apr 10, 2010·Nature Reviews. Molecular Cell Biology·Bart VanhaesebroeckBenoit Bilanges
Jan 14, 2012·Expert Opinion on Therapeutic Targets·Chandra Bartholomeusz, Ana Maria Gonzalez-Angulo
Feb 22, 2012·Current Oncology Reports·Lise WillemsDidier Bouscary
Feb 24, 2012·Nature Reviews. Molecular Cell Biology·Bart VanhaesebroeckPhillip Hawkins
May 24, 2012·Neuro-oncology·Patrick Y WenW K Alfred Yung
Sep 12, 2012·Chembiochem : a European Journal of Chemical Biology·Matthias P Wymann, Carsten Schultz
Feb 13, 2013·Nature Reviews. Clinical Oncology·Jordi RodonJosep Tabernero
Jun 4, 2013·Bioorganic & Medicinal Chemistry Letters·Pascal FuretGiorgio Caravatti
Jul 4, 2013·Bioorganic & Medicinal Chemistry Letters·Sabina PecchiCharles F Voliva
Feb 1, 2014·Nature Reviews. Drug Discovery·David A Fruman, Christian Rommel
Jan 13, 2011·ACS Medicinal Chemistry Letters·Matthew T BurgerSabina Pecchi
Jun 20, 2014·Future Medicinal Chemistry·Yujeong JeongSungwoo Hong
Jan 15, 2015·Cancer Cell·David W CesconTak W Mak
Jan 17, 2015·Critical Reviews in Oncology/hematology·Dionysios Papadatos-PastosDebashis Sarker
Feb 14, 2015·Gynecologic Oncology·Seiji MabuchiTomoyuki Sasano
Jun 23, 2015·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Johan F VansteenkisteJean-Charles Soria
Sep 4, 2015·Journal of the Advanced Practitioner in Oncology·Nicholas Forcello, Nidhi Saraiya

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.